Combination therapy with afatinib and bevacizumab in an EGFR-mutated non-small cell lung cancer patient with acquired ERBB2 amplification: A case report

INTRODUCTION: Acquired resistance to reversible EGFR tyrosine kinase inhibitors remains a significant obstacle, and acquired ERBB2 amplification is the most common “bypass” mechanism. For patients with sensitizing EGFR mutation who experience resistance via ERBB2 amplification, no targeted drug has...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Sixian, Xiang, Tianmin, Lu, Wei, Hong, Shuiqiang, Li, Yuanyuan, Lu, Yuan, Zhang, Qiongyue, Chen, Yongfeng, Zhou, Suli, Wang, Gehui, Zhang, Zhenzhen, Cai, Yongguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7909148/
https://www.ncbi.nlm.nih.gov/pubmed/33663050
http://dx.doi.org/10.1097/MD.0000000000024380

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7909148/
https://www.ncbi.nlm.nih.gov/pubmed/33663050
http://dx.doi.org/10.1097/MD.0000000000024380

Ejemplares similares